MedTrace Logo

Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)

NCT03743103 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-02-09

No results posted yet for this study

Summary

Because of its pharmacokinetic characteristics, such as short half-life and its safety profile, esmolol hydrochloride is a beta blocker suitable for venous use in the form of continuous infusion. Strategies that improve the blood pressure control of patients with hemorrhagic stroke during the first hours of hospitalization are determinant in controlling the hematoma expansion and determining factor in its prognosis. This study was designed with the objective of evaluating the beneficial effects of combining esmolol hydrochloride with sodium nitroprusside for the blood pressure control of participants with hemorrhagic stroke.

Conditions

  • Hemorrhagic Stroke

Interventions

DRUG

Brevibloc, 10 Mg/mL Intravenous Solution

10 mL/h every 5 minutes until reaching the pressure target

DRUG

Nitroprusside, Sodium

0.5 ug/kg/min every 3 minutes until reaching the pressure target

Sponsors & Collaborators

  • Cristália Produtos Químicos Farmacêuticos Ltda.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-18
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03743103 on ClinicalTrials.gov